| Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis SM Rowe, SL Heltshe, T Gonska, SH Donaldson, D Borowitz, D Gelfond, ... American journal of respiratory and critical care medicine 190 (2), 175-184, 2014 | 553 | 2014 |
| Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections KB Hisert, SL Heltshe, C Pope, P Jorth, X Wu, RM Edwards, M Radey, ... American journal of respiratory and critical care medicine 195 (12), 1617-1628, 2017 | 395 | 2017 |
| SpiroSmart: using a microphone to measure lung function on a mobile phone EC Larson, M Goel, G Boriello, S Heltshe, M Rosenfeld, SN Patel Proceedings of the 2012 ACM Conference on ubiquitous computing, 280-289, 2012 | 314 | 2012 |
| Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial DP Nichols, AC Paynter, SL Heltshe, SH Donaldson, CA Frederick, ... American journal of respiratory and critical care medicine 205 (5), 529-539, 2022 | 287 | 2022 |
| Risk of total and aggressive prostate cancer and pesticide use in the Agricultural Health Study S Koutros, LE Beane Freeman, JH Lubin, SL Heltshe, G Andreotti, ... American journal of epidemiology 177 (1), 59-74, 2013 | 235 | 2013 |
| Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor SL Heltshe, N Mayer-Hamblett, JL Burns, U Khan, A Baines, BW Ramsey, ... Clinical infectious diseases 60 (5), 703-712, 2015 | 234 | 2015 |
| Late diagnosis defines a unique population of long-term survivors of cystic fibrosis DM Rodman, JM Polis, SL Heltshe, MK Sontag, C Chacon, RV Rodman, ... American journal of respiratory and critical care medicine 171 (6), 621-626, 2005 | 210 | 2005 |
| Occupational exposure to pesticides and bladder cancer risk S Koutros, DT Silverman, MCR Alavanja, G Andreotti, CC Lerro, S Heltshe, ... International journal of epidemiology 45 (3), 792-805, 2016 | 177 | 2016 |
| Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data FJ Accurso, F Van Goor, J Zha, AJ Stone, Q Dong, CL Ordonez, SM Rowe, ... Journal of Cystic Fibrosis 13 (2), 139-147, 2014 | 162 | 2014 |
| Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation JK Harris, BD Wagner, ET Zemanick, CE Robertson, MJ Stevens, ... Annals of the American Thoracic Society 17 (2), 212-220, 2020 | 153 | 2020 |
| Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: a statistical perspective for the clinical researcher R Szczesniak, SL Heltshe, S Stanojevic, N Mayer-Hamblett Journal of Cystic Fibrosis 16 (3), 318-326, 2017 | 151 | 2017 |
| Multiple-breath washout as a lung function test in cystic fibrosis. A cystic fibrosis foundation workshop report P Subbarao, C Milla, P Aurora, JC Davies, SD Davis, GL Hall, S Heltshe, ... Annals of the American Thoracic Society 12 (6), 932-939, 2015 | 147 | 2015 |
| A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic … MW Konstan, G Döring, SL Heltshe, LC Lands, KA Hilliard, P Koker, ... Journal of Cystic Fibrosis 13 (2), 148-155, 2014 | 145 | 2014 |
| Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis O Manor, R Levy, CE Pope, HS Hayden, MJ Brittnacher, R Carr, ... Scientific reports 6 (1), 22493, 2016 | 138 | 2016 |
| Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation D Gelfond, S Heltshe, C Ma, SM Rowe, C Frederick, A Uluer, L Sicilian, ... Clinical and translational gastroenterology 8 (3), e81, 2017 | 136 | 2017 |
| Escherichia coli Dysbiosis Correlates With Gastrointestinal Dysfunction in Children With Cystic Fibrosis LR Hoffman, CE Pope, HS Hayden, S Heltshe, R Levy, S McNamara, ... Clinical infectious diseases 58 (3), 396-399, 2014 | 117 | 2014 |
| Heterogeneity in survival in adult patients with cystic fibrosis with FEV1< 30% of predicted in the United States KJ Ramos, BS Quon, SL Heltshe, N Mayer-Hamblett, ED Lease, ... Chest 151 (6), 1320-1328, 2017 | 113 | 2017 |
| Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist DP Nichols, SJ Morgan, M Skalland, AT Vo, JM Van Dalfsen, SBP Singh, ... The Journal of Clinical Investigation 133 (10), 2023 | 111 | 2023 |
| GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator … SM Rowe, SL Heltshe, T Gonska, SH Donaldson, D Borowitz, D Gelfond, ... Am J Respir Crit Care Med 190 (2), 175-84, 2014 | 110 | 2014 |
| Functional and psychosocial outcomes of older adults after burn injury: results from a multicenter database of severe burn injury MB Klein, DC Lezotte, S Heltshe, J Fauerbach, RK Holavanahalli, ... Journal of burn care & research 32 (1), 66-78, 2011 | 108 | 2011 |
